Several lines of evidence have shown that rituximab (RTX)-treated patients are at high risk of severe coronavirus disease 2019 (COVID-19).1 Thus, health authorities have considered patients receiving RTX as extremely high priority for anti-SARS-CoV-2 vaccination.